TriangleNCT00721513 · OUTCOME
Best Overall Response Rate
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- COUNT_OF_PARTICIPANTS
- Unit
- Participants
- Interval / dispersion
- Not reported
- Time frame
- up to 2 years
What was measured
Defined as rate of complete and partial responses (at least 30% decrease in the sum of the longest diameter of target lesions), measured by CT scan or MRI of the head and neck after completion of multimodality treatment with induction TPF (Docetaxel, cisplatin and fluorouracil) chemotherapy followed by combined ERT. We will use RECIST (Response Evaluation Criteria In Solid Tumors) (Therasse et al, 2000) for evaluation of response.
Groups in this outcome
TPFChemotherapy + Concomitant Cetuximab & RT
Taxotere/Cisplatinum/5-Fluorouracil (TPF) Chemotherapy Followed by Concomitant Cetuximab \& Radiation Therapy cetuximab cisplatin docetaxel fluorouracil computed tomography positron emission tomography quality-of-life assessment 3-dimensional conformal radiation therapy intensity-modulated radiation therapy
| Group | Source count |
|---|---|
| TPFChemotherapy + Concomitant Cetuximab & RT | 20 |
Reported measurements
Source class 1
Complete response
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| TPFChemotherapy + Concomitant Cetuximab & RT | 5 | Not reported | Not reported | Not reported | Not reported |
Partial response
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| TPFChemotherapy + Concomitant Cetuximab & RT | 10 | Not reported | Not reported | Not reported | Not reported |
Progression of disease
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| TPFChemotherapy + Concomitant Cetuximab & RT | 4 | Not reported | Not reported | Not reported | Not reported |
Stable disease
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| TPFChemotherapy + Concomitant Cetuximab & RT | 1 | Not reported | Not reported | Not reported | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- value
- 5
- title
- Complete response
- measurements
- group Id
- OG000
- value
- 10
- title
- Partial response
- measurements
- group Id
- OG000
- value
- 4
- title
- Progression of disease
- measurements
- group Id
- OG000
- value
- 1
- title
- Stable disease
- denoms
- counts
- group Id
- OG000
- value
- 20
- units
- Participants
- description
- Defined as rate of complete and partial responses (at least 30% decrease in the sum of the longest diameter of target lesions), measured by CT scan or MRI of the head and neck after completion of multimodality treatment with induction TPF (Docetaxel, cisplatin and fluorouracil) chemotherapy followed by combined ERT. We will use RECIST (Response Evaluation Criteria In Solid Tumors) (Therasse et al, 2000) for evaluation of response.
- groups
- description
- Taxotere/Cisplatinum/5-Fluorouracil (TPF) Chemotherapy Followed by Concomitant Cetuximab \& Radiation Therapy cetuximab cisplatin docetaxel fluorouracil computed tomography positron emission tomography quality-of-life assessment 3-dimensional conformal radiation therapy intensity-modulated radiation therapy
- id
- OG000
- title
- TPFChemotherapy + Concomitant Cetuximab & RT
- param Type
- COUNT_OF_PARTICIPANTS
- reporting Status
- POSTED
- time Frame
- up to 2 years
- title
- Best Overall Response Rate
- type
- SECONDARY
- unit Of Measure
- Participants
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice